Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2016 1
2021 1
2022 9
2023 5
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Estimated Effectiveness of a Primary Cycle of Protein Recombinant Vaccine NVX-CoV2373 Against COVID-19.
Mateo-Urdiales A, Sacco C, Petrone D, Bella A, Riccardo F, Del Manso M, Bressi M, Siddu A, Brusaferro S, Palamara AT, Rezza G, Pezzotti P, Fabiani M; Italian National COVID-19 Integrated Surveillance System and the Italian COVID-19 vaccines registry. Mateo-Urdiales A, et al. Among authors: bressi m. JAMA Netw Open. 2023 Oct 2;6(10):e2336854. doi: 10.1001/jamanetworkopen.2023.36854. JAMA Netw Open. 2023. PMID: 37792377 Free PMC article.
Guillain-Barré syndrome in patients dying with COVID-19 in Italy: a retrospective study.
Colaizzo E, Puopolo M, Tiple D, Vaianella L, Vanacore N, Milanese A, Palmieri L, Lo Noce C, Canevelli M, Perna A, Onder G; Italian National Institute of Health COVID-19 Mortality Group. Colaizzo E, et al. Ann Ist Super Sanita. 2023 Jul-Sep;59(3):194-198. doi: 10.4415/ANN_23_03_04. Ann Ist Super Sanita. 2023. PMID: 37712236 Free article.
Microbiologically confirmed infections and antibiotic-resistance in a national surveillance study of hospitalised patients who died with COVID-19, Italy 2020-2021.
Floridia M, Giuliano M, Monaco M, Palmieri L, Lo Noce C, Palamara AT, Pantosti A, Brusaferro S, Onder G; Italian National Institute of Health COVID-19 Mortality Group. Floridia M, et al. Antimicrob Resist Infect Control. 2022 May 21;11(1):74. doi: 10.1186/s13756-022-01113-y. Antimicrob Resist Infect Control. 2022. PMID: 35598032 Free PMC article. Review.
Characteristics of COVID-19 cases in Italy from a sex/gender perspective.
D'Archivio M, Cataldo C, Del Manso M, Petrone D, Sacco C, Vescio MF, Spuri M, Rota MC, Bressi M, Fabiani M, Boros S, Urdiales AM, Riccardo F, Bella A, Masella R, Pezzotti P, Busani L. D'Archivio M, et al. Among authors: bressi m. Ann Ist Super Sanita. 2022 Oct-Dec;58(4):227-235. doi: 10.4415/ANN_22_04_02. Ann Ist Super Sanita. 2022. PMID: 36511193 Free article.
Risk and protective factors for SARS-CoV-2 reinfections, surveillance data, Italy, August 2021 to March 2022.
Sacco C, Petrone D, Del Manso M, Mateo-Urdiales A, Fabiani M, Bressi M, Bella A, Pezzotti P, Rota MC, Riccardo F; Italian Integrated Surveillance of COVID-19 study group. Sacco C, et al. Among authors: bressi m. Euro Surveill. 2022 May;27(20):2200372. doi: 10.2807/1560-7917.ES.2022.27.20.2200372. Euro Surveill. 2022. PMID: 35593164 Free PMC article.
Protection against severe COVID-19 after second booster dose of adapted bivalent (original/Omicron BA.4-5) mRNA vaccine in persons ≥ 60 years, by time since infection, Italy, 12 September to 11 December 2022.
Fabiani M, Mateo-Urdiales A, Sacco C, Fotakis EA, Rota MC, Petrone D, Bressi M, Del Manso M, Siddu A, Fedele G, Stefanelli P, Bella A, Riccardo F, Palamara AT, Rezza G, Brusaferro S, Pezzotti P; Italian Integrated Surveillance of COVID-19 study group and of the Italian COVID-19 Vaccines Registry group. Fabiani M, et al. Among authors: bressi m. Euro Surveill. 2023 Feb;28(8):2300105. doi: 10.2807/1560-7917.ES.2023.28.8.2300105. Euro Surveill. 2023. PMID: 36820640 Free PMC article.
Status and characteristics of ambient PM2.5 pollution in global megacities.
Cheng Z, Luo L, Wang S, Wang Y, Sharma S, Shimadera H, Wang X, Bressi M, de Miranda RM, Jiang J, Zhou W, Fajardo O, Yan N, Hao J. Cheng Z, et al. Among authors: bressi m. Environ Int. 2016 Apr-May;89-90:212-21. doi: 10.1016/j.envint.2016.02.003. Epub 2016 Feb 15. Environ Int. 2016. PMID: 26891184
Relative effectiveness of a 2nd booster dose of COVID-19 mRNA vaccine up to four months post administration in individuals aged 80 years or more in Italy: A retrospective matched cohort study.
Fabiani M, Mateo-Urdiales A, Sacco C, Rota MC, Petrone D, Bressi M, Del Manso M, Siddu A, Proietti V, Battilomo S, Menniti-Ippolito F, Popoli P, Bella A, Riccardo F, Palamara AT, Rezza G, Brusaferro S, Pezzotti P; Italian Integrated Surveillance of COVID-19 study group, of the Italian COVID-19 Vaccines Registry group. Fabiani M, et al. Among authors: bressi m. Vaccine. 2023 Jan 4;41(1):76-84. doi: 10.1016/j.vaccine.2022.11.013. Epub 2022 Nov 14. Vaccine. 2023. PMID: 36400660 Free PMC article.
Relative effectiveness of monovalent and bivalent mRNA boosters in preventing severe COVID-19 due to omicron BA.5 infection up to 4 months post-administration in people aged 60 years or older in Italy: a retrospective matched cohort study.
Mateo-Urdiales A, Sacco C, Fotakis EA, Del Manso M, Bella A, Riccardo F, Bressi M, Rota MC, Petrone D, Siddu A, Fedele G, Stefanelli P, Palamara AT, Brusaferro S, Rezza G, Pezzotti P, Fabiani M. Mateo-Urdiales A, et al. Among authors: bressi m. Lancet Infect Dis. 2023 Dec;23(12):1349-1359. doi: 10.1016/S1473-3099(23)00374-2. Epub 2023 Jul 18. Lancet Infect Dis. 2023. PMID: 37478877
16 results